
    
      To evaluate the safety and efficacy of rhTNK-tPA at different doses of 0.10 mg/kg, 0.25 mg/kg
      and 0.32 mg/kg compared with standard rt-PA intravenous thrombolytic therapy within 3 hours
      after onset of ischemic stroke. The primary objective of this study is to evaluate the
      differences of NIHSS scores among the four treatment groups at 14 days after intravenous
      thrombolysis.
    
  